Agency for Medicinal Products and Medical Devices, Zagreb, Croatia.
Laboratory for Pain Research, School of Medicine, University of Split, Split, Croatia.
Ther Clin Risk Manag. 2015 Aug 28;11:1305-14. doi: 10.2147/TCRM.S86226. eCollection 2015.
The increased consumption of analgesics has been documented worldwide during the last 2 decades. The aim of the study was to examine the trends in opioid and nonopioid analgesic consumption in Croatia between 2007 and 2013.
Data on opioid consumption were extracted from the database of the national authority. All opioid and nonopioid analgesics were included in the analysis. Data were presented as defined daily doses per 1,000 inhabitants per day. Adequacy of opioid consumption was calculated using adequacy of consumption measure.
During the examined 7-year period, the total consumption and total cost of all analgesics in Croatia showed continuous increase. In the M01A group (anti-inflammatory and antirheumatic products, nonsteroids), ibuprofen had an exponential increasing trend, and in 2011, it overtook diclofenac consumption. Ibuprofen and diclofenac had the highest consumption also in the M02A group of topical products for joint and muscular pain. Tramadol was by far the most consumed type of opioids (N02A group) and paracetamol in the group of other analgesics and antipyretics (N02B). The adequacy of consumption measure value was 0.19, indicating that Croatia is a country with a low opioid consumption.
Between 2007 and 2013, both consumption of analgesics and their cost in Croatia had an increasing trend. Comparisons with data from other countries, based on the published literature, indicate that analgesic consumption in Croatia is still relatively low. Calculation of the adequacy of opioid consumption indicated that Croatia is a country with low opioid consumption. Further studies are necessary for establishing whether current analgesic consumption in Croatia corresponds to patient needs.
在过去的 20 年中,全世界都记录到镇痛药的消耗量增加。本研究的目的是检验 2007 年至 2013 年期间克罗地亚阿片类药物和非阿片类药物消耗的趋势。
从国家主管部门的数据库中提取阿片类药物消耗数据。所有阿片类药物和非阿片类药物均包括在分析中。数据以每 1000 居民每天的定义日剂量表示。使用消耗适宜度测量法计算阿片类药物消耗的适宜度。
在所研究的 7 年期间,克罗地亚所有镇痛药的总消耗量和总成本持续增加。在 M01A 组(抗炎和抗风湿产品,非甾体类)中,布洛芬呈指数增长趋势,2011 年超过了双氯芬酸的消耗量。布洛芬和双氯芬酸在 M02A 组(用于关节和肌肉疼痛的局部产品)中也具有最高的消耗量。曲马多是迄今为止最消耗的阿片类药物(N02A 组),扑热息痛在其他镇痛药和解热药(N02B)组中消耗量最大。消耗适宜度测量值为 0.19,表明克罗地亚是一个阿片类药物消耗低的国家。
2007 年至 2013 年期间,克罗地亚的镇痛药消耗及其成本均呈上升趋势。与基于已发表文献的其他国家的数据进行比较表明,克罗地亚的镇痛药消耗仍然相对较低。计算阿片类药物消耗的适宜度表明,克罗地亚是一个阿片类药物消耗低的国家。需要进一步研究以确定克罗地亚目前的镇痛药消耗是否符合患者需求。